Zusammengesetzter Bewertungsbereich · konservativ ¥68–¥70 / fair ¥98–¥132 / optimistisch ¥161–¥176. Bei ¥162.95, Innerhalb des optimistischen Bereichs des inneren Werts · viele Erwartungen eingepreist.
Bei Veröffentlichung ¥128.7 (24. Juni 2026)
Asymchem said it signed an MoU with Tianjin TEDA to further expand TIDES drug service capabilities.
Possible impact:May affect expectations for growth in peptide, oligonucleotide and broader TIDES CDMO services.
A subsidiary disclosed EIA information for an innovative drug production service platform expansion at its chemical macromolecule site.
Possible impact:May shape expectations for chemical macromolecule capacity expansion and capex timing.
Asymchem published its 2025 annual performance report, updating full-year operating and financial information.
Possible impact:May affect expectations for earnings recovery, order trends and the 2026 performance base.
A subsidiary disclosed the second EIA notice for phase IV chemical macromolecule expansion, including a new production building and support facilities.
Possible impact:May affect expectations for macromolecule synthesis capacity release and medium-term order intake capability.
Asymchem released its 2025 annual performance materials, citing double-digit revenue and profit growth and improved efficiency.
Possible impact:May affect expectations for CDMO demand recovery, earnings resilience and valuation recovery pace.
Automatically summarized from public sources; for context only, not investment advice.
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities. The company was founded in 1998 and is headquartered in Tianjin, China.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.